NEW YORK, March 27 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation announced that it has awarded approximately $2.1 million total to seven research teams working to improve drug delivery for Parkinson's disease.
The funding was awarded under the Foundation's Improving Delivery of Parkinson's Disease Therapeutics to the Brain. The program is designed to address two major challenges to the development of transformative treatments for Parkinson's disease: the need for non-invasive drug delivery technologies allowing therapeutics to cross the blood-brain barrier, and the need to more precisely understand how molecules move inside the central nervous system in order to target treatments to specific regions of the brain.
Funded projects are listed below. Full information on funded projects, including grant abstracts and researcher bios, is available on the Foundation's Searchable Database of Funded Grants.
Image-guided Gene Delivery for Parkinson's
Krysztof Bankiewicz, M.D., Ph.D., University of California, San Francisco
Convection Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Human Parkinson's Disease
Jeff Elias, M.D., University of Virginia, and Russell Lonser, M.D., National Institute of Neurodegenerative Disease and Stroke
Real-time Monitoring of Targeting, Delivery, and Spread of Therapeutic Agents in the Brain
Samir Jafri, Ph.D., University of Maryland, Baltimore, and Cha-Min Tang, M.D., Ph.D., University of Maryland School of Medicine
Utilizing Novel Tracers to Determine the Distribution of Therapeutic Agents In Vivo
RamakrishnaVenugopalan, Ph.D., Codman and Shurtleff, Inc.
'/>"/>SOURCE Michael J. Fox Foundation Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine technology :1.
Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development2.
Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease3.
New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials4.
Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative5.
Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine6.
The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards7.
Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease8.
Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics9.
Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee10.
Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 200811.
Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease